hCAIX/XII-IN-6
hCAIX/XII-IN-6 is an orally active carbonic anhydrase (CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA).
For research use only. We do not sell to patients.
- CAS No.: 3031666-31-3
- Formula: C26H23N3O6S4
- Molecular Weight:601.74
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
hCA II 2950 nM (Ki) |
hCA IX 4.1 nM (Ki) |
hCA XII 7.7 nM (Ki) |
In Vitro
hCAIX/XII-IN-6 has inhibition activitr for human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively[1][1].
hCAIX/XII-IN-6 (150 μM) exhibits a weaker H2S releas[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:adjuvant-induced arthritis rat model[1]
-
Dosage:1, 10, 30 mg/kg
-
Administration:oral, single
-
Result:Evoked an antihypersensitivity effect in a dose-dependent manner.
Reduced spontaneous pain in a dose-dependent manner with a peak of efficacy between 30 and 45 min.
Chemical Information
-
CAS No. 3031666-31-3
-
Molecular Weight 601.74
-
Formula C26H23N3O6S4
-
SMILES
O=C(N(CC1=CC=C([N+]([O-])=O)C=C1OC)CCC2=CC=C(S(=O)(N)=O)C=C2)C3=CC=C(C4=CSSC4=S)C=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
hCAIX/XII-IN-6 Related Classifications
HY-151472 Related Classifications
Powered by Bioz